Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL02 in Severe Pneumococcal Pneumonia
NCT02583373Phase 1Completed
- Sponsor
- Combioxin SA
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CAL02 in community acquired pneumonia (CAP) (3 arms), sponsored by Combioxin SA. Primary endpoint: Frequency, severity and characteristics of adverse events at 29 days. Started Mar 2016; status: completed.
02
Drugs
CAL02
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02583373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583373.